Lupeng Pharma Closes $35 Million Pre-B Funding for Novel Drugs
July 30, 2021 at 06:01 AM EDT
Guangzhou Lupeng Pharmaceutical completed a $35 million pre-B financing led by Temasek. The company will use the funds for global clinical development of its lead drug, a selective Bcl-2 inhibitor, along with advancing at least four other candidates into clinical trials. Founded in 2018, Lupeng aims to develop global best-in-class therapies. The company develops novel small molecule drugs for cancer, hepatitis B and autoimmune diseases. Lupeng is approved to conduct clinical trials of its lead Bcl-2 inhibitor in China , the US , the UK and Spain for advanced lymphoma indications. More details.... Share this with colleagues: // //
